Literature DB >> 6469937

Naltrexone treatment in a jail work-release program.

L S Brahen, R K Henderson, T Capone, N Kordal.   

Abstract

Inmates with a history of opiate addiction have traditionally been excluded from jail work-release programs because of their high likelihood of returning to drug use. In 1972, a new jail work-release program was begun in the Nassau County (New York) Jail, to which addicted inmates, who had formerly been excluded automatically, could request admission if they took the opiate blocking agent naltrexone. Inmates received naltrexone twice a week and had routine urine checks for drugs of abuse and an alcohol breath test when indicated. Psychological and vocational testing and weekly psychotherapy sessions were provided. For those no longer incarcerated, the adjacent hospital outpatient clinic was available for naltrexone treatment. Naltrexone has proved to be a completely effective opiate blocking agent with no major side effects in 691 patients over a 10-year period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469937

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  A categorical typology of naltrexone-adopting private substance abuse treatment centers.

Authors:  Carrie B Oser; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2007-11-07

Review 3.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

4.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

Review 5.  Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.

Authors:  Nikolaj Kunøe; Philipp Lobmaier; Hanh Ngo; Gary Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 6.  Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Min Zhao; Suzanne Nielsen; Matthew Torrington; Karen Miotto
Journal:  Subst Abuse Rehabil       Date:  2011-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.